Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign)

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1151-1158

  Chen, Eric ^a   Brown, David M ^a   Benz, Matthew S ^a   Fish, Richard H ^a   Wong, Tien P ^a   Kim, Rosa Y ^a   Major, James C ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Drug toxicity; Hydroxychloroquine; Photoreceptors; Screening test; Spectral domain optical coherence tomography

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; AGED; ARTICLE; AUTOMATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; EARLY DIAGNOSIS; EYE EXAMINATION; EYE FUNDUS; FEASIBILITY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT REFERRAL; PERIMETRY; PHOTORECEPTOR; RECOMMENDED DRUG DOSE; RETINA FOVEA; RETINA MACULA LUTEA; RETINOPATHY; RETROSPECTIVE STUDY; SCREENING TEST;

EID: 78650711806     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S14257     Document Type: Article

References (27)

1. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110(7):1321-1326.
2. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40(8):1482-1486.
3. Lee AG. Hydroxychloroquine screening. Br J Ophthalmol. 2005;89(5): 521-522.
4. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2002;109(7):1377-1382.
5. Marmor MF. The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. Am J Ophthalmol. 2005;140(5): 894-895.
6. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12(4):294-304.
7. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol. 2008;23(3):201-209.
8. Elder M, Rahman AM, McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol. 2006;124(12): 1729-1733.
9. Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001;358(9284):813-814.
10. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol. 1999;140(1):3-7.
11. Duncker G, Schmiederer M, Bredehorn T. Chloroquine-induced lipidosis in the rat retina: a functional and morphological study. Ophthalmologica. 1995;209(2):79-83.
12. Duncker G, Bredehorn T. Chloroquine-induced lipidosis in the rat retina: functional and morphological changes after withdrawal of the drug. Graefes Arch Clin Exp Ophthalmol. 1996;234(6):378-381.
13. Hallberg A, Naeser P, Andersson A. Effects of long-term chloroquine exposure on the phospholipid metabolism in retina and pigment epithelium of the mouse. Acta Ophthalmol (Copenh). 1990;68(2):125-130.
14. Pasadhika S, Fishman GA. Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures. Eye (Lond). 2010; 24(2):340-346.
15. Pasadhika S, Fishman GA, Choi D, Shahidi M. Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity. Eye (Lond). 2010;24(5):756-762;quiz 763.
16. Rodriguez-Padilla JA, Hedges TR 3rd, Monson B, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007;125(6):775-780.
17. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin. 1999;39(2):49-57.
18. Semmer AE, Lee MS, Harrison AR, Olsen TW. Hydroxychloroquine retinopathy screening. Br J Ophthalmol. 2008;92(12):1653-1655.
19. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/ hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47(8): 3531-3538.
20. Anderson C, Pahk P, Blaha GR, et al. Preferential hyperacuity perimetry to detect hydroxychloroquine retinal toxicity. Retina. 2009;29(8): 1188-1192.
21. Chang WH, Katz BJ, Warner JE, Vitale AT, Creel D, Digre KB. A novel method for screening the multifocal electroretonogram in patients using hydroxychloroquine. Retina. 2008;28(10):1478-1486.
22. Lai TY, Chan WM, Li H, Lai RY, Lam DS. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol. 2005;140(5):794-807.
23. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007;143(5):801-809.
24. Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 2004;122(7):973-981.
25. Stepien KE, Han DP, Schell J, Godara P, Rha J, Carroll J. Spectraldomain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. Trans Am Ophthalmol Soc. 2009;107:28-33.
26. Kelmenson AT, Brar VS, Murthy RK, Chalam KV. Fundus autofluorescence and spectral domain optical coherence tomography in early detection of Plaquenil maculopathy. Eur J Ophthalmol. 2009;20(4):785-788.
27. Brinkley JR Jr, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol. 1979; 88(1):1-11.